secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001140361-25-029343
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q2 net loss $321.7M ($1.70/sh); ARIKAYCE revenue $107.4M (+19% YoY)
--------------------------------------------------------------------------

- ARIKAYCE global revenue $107.4M, up 19% vs Q2 2024; US revenue $68.7M (+7.7%).
- Net loss $321.7M vs $300.6M a year ago; R&D spend $177.2M, SG&A $154.8M on brensocatib launch prep.
- Cash & securities $1.9B; full-year ARIKAYCE revenue guidance reaffirmed at $405-425M.
- Brensocatib PDUFA date Aug 12, 2025; Phase 3 TPIP in PH-ILD to start H2 2025.
- Completed $823.1M equity offering in June; redeemed $569.5M convertible notes in April/May.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/0001140361-25-029343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-029343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer